Stemcell treatment for hair and skin, Autologous Adipose Stem Cell Treatment
Through the history of stem cell therapy and stem cell research, animal stem cells have been used, human embryonic stem cells, and now research has led us to...

By: Ojas Aesthetic

See the original post here:
Stemcell treatment for hair and skin, Autologous Adipose Stem Cell Treatment - Video

stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india short
improvement seen in just 4 months after stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india. Stem Cell Therapy done date 2nd ...

By: Neurogen Brain and Spine Institute

Continued here:
stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india short - Video

By Dalia Dangerfield, Reporter Last Updated: Saturday, December 14, 2013, 8:48 PM TAMPA --

USF researchers believe stem cell therapy can help men and women with mild brain injuries.

This is quite a phenomenal observation, said Dr. Cesar Borlongan, a neuroscientist from USF Health. In our hands, stem cell therapy may offer this hope for the soldiers to prevent the progression of the disease and hopefully we can stop the disease process at the early stage."

In a recent study Borlongan injected adult stem cells in rats with traumatic brain injury. The stem cells served as a bridge, allowing new brain cells to move up to the damaged part of the brain.

That's a new concept, it's like the cells are very smart, said Borlongan.

Over time the adult stem cells helped partially repair the brain damage in rats.

Professor Borlongan believes the same may be true for humans allowing them to slowly get better.

Follow this link:
New study shows stem cell therapy helps brain injuries

Parkinson's patient Ed Fitzpatrick speaks about stem cell research for his disease. Fitzpatrick talked on a Dec. 7 panel at the World Stem Cell Summit in San Diego. Bradley J. Fikes

Parkinson's patient Ed Fitzpatrick speaks about stem cell research for his disease. Fitzpatrick talked on a Dec. 7 panel at the World Stem Cell Summit in San Diego.

For eight local Parkinsons patients seeking treatment with stem cell technology, 2014 could bring the milestone theyve been anticipating.

If all goes well, the U.S. Food and Drug Administration will approve an attempt to replace the brain cells destroyed in Parkinsons. The new cells, grown from each patients own skin cells, are expected to restore normal movement in the patients.

Because the new brain cells are made from the patients own cells, immunosuppressive drugs shouldnt be needed. Ideally, patients could stop taking their medications and resume normal activities for many years, or even the rest of their lives.

The project, Summit4StemCell.org, is a collaboration between three nonprofits. The Scripps Research Institute handles the science; Scripps Clinic takes care of the medical side; and the Parkinsons Association of San Diego helps to raise money for the self-funded project.

Since 2011, the focus has been at the institute, where scientists led by Jeanne Loring have made the artificial embryonic stem cells, called induced pluripotent stem cells, and turned them into the needed brain cells. Now Scripps Clinic is assuming a more prominent role to prepare for treating the patients.

A study in rats began in early December; results are expected by April. The animal study is meant to assess safety, although researchers will also look for signs of effectiveness.

In January, scientists will visit the FDA to lay the groundwork for a formal application, said Scripps Clinic neurologist Melissa Houser, who treats all eight patients.

Success in the animal study will likely result in a go-ahead, Houser said. If the animal trial fails, its back to the drawing board.

Here is the original post:
Parkinson’s stem cell project aims for 2014 approval

PUBLIC RELEASE DATE:

12-Dec-2013

Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles

Stem cell researchers from UCLA have published the first study to identify the origin cells and track the early development of human articular cartilage, providing what could be a new cell source and biological roadmap for therapies to repair cartilage defects and damage from osteoarthritis.

Such transformative therapies could reach clinical trials within three years, said the scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.

The study, led by Dr. Denis Evseenko, an assistant professor of orthopedic surgery and head of UCLA's Laboratory of Connective Tissue Regeneration, was published online Dec. 12 in the journal Stem Cell Reports and will appear in a forthcoming print edition.

Articular cartilage, a highly specialized tissue formed from cells called chondrocytes, protects the bones of joints from forces associated with load-bearing and impact and allows nearly frictionless motion between the articular surfaces the areas where bone connects with other bones in a joint.

Cartilage injury and a lack of cartilage regeneration often lead to osteoarthritis, which involves the degradation of joints, including cartilage and bone. Osteoarthritis currently affects more than 20 million people in the U.S., making joint-surface restoration a major priority in modern medicine.

While scientists have studied the ability of different cell types to generate articular cartilage, none of the current cell-based repair strategies including expanded articular chondrocytes or mesenchymal stromal cells from adult bone marrow, adipose tissue, sinovium or amniotic fluid have generated long-lasting articular cartilage tissue in the laboratory.

For the current study, Evseenko and his colleagues used complex molecular biology techniques to determine which cells grown from embryonic stem cells, which can become any cell type in the body, were the progenitors of cartilage cells, or chondrocytes. They then tested and confirmed the growth of these progenitor cells into cartilage cells and monitored their growth progress, observing and recording important genetic features, or landmarks, that indicated the growth stages of these cells as they developed into the cartilage cells.

Visit link:
UCLA stem cell scientists first to track joint cartilage development in humans

Poway, California (PRWEB) December 13, 2013

Noni is a ten-year-old released Canine Companion for Independence dog who just achieved her Master Agility Champion status after the pain from arthritis tried to slow her down. Nonis owner, Dr. Kim Dembinski, a veterinarian at Paradise Veterinary Hospital in San Diego turned to stem cell therapy by Vet-Stem, Inc. and fellow colleague Dr. Jennipher Harris to help Noni.

When Dr. Dembinski noticed weakness and discomfort in her aging agility dog she was proactive in keeping Noni happy and comfortable, The main thought was that she gives so much between therapy work, being my best friend, and as the clinic mascot that giving her relief from pain and her being more comfortable was the least I could do for her.

Nonis stem cell therapy involved a small fat sample collection, which was brought to Vet-Stems lab in Poway, California. There, highly trained lab technicians processed Nonis fat tissue to isolate the stem cells into doses that could be injected into the arthritic joints that were causing her pain. Normally the tissue is shipped overnight to Vet-Stem and the cells are shipped overnight back to the veterinarian making doses available within 48 hours, but because Paradise Veterinary Hospital is located near Vet-Stem Nonis stem cell doses were available for injection the same day the fat sample was collected.

Noni did very well post procedure; she regained muscle strength and flexibility, Dr. Dembinski reported, Noni did four weeks of rehab then went right back to competing in agility. Six months after the procedure she earned her MACH (Master Agility Champion), AKC (American Kennel Club) title. Because of her stem cell therapy she is still comfortable and playing agility!

Dr. Dembinski is a general practitioner for pets including dogs, cats, small mammals, birds and exotics. She is currently owner and primary veterinarian at Paradise Veterinary Hospital and sits on the board of the San Diego County Veterinary Medical Association. Caring for animals is not just a job for Dr. Dembinski, it is a passion. In her free time she and Noni compete in dog agility trials with AKC, North American Dog Agility Council and Canine Performance Events.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Go here to read the rest:
San Diego Canine Overcomes Pain to Achieve Championship with the Help of Paradise Veterinary Hospital and Vet-Stem, Inc.

Contact Information

Available for logged-in reporters only

Newswise Scientists from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are bringing stem cell science funded by the California Institute of Regenerative Medicine (CIRM), the state stem cell agency, directly to patients in two exciting new clinical trials scheduled to begin in early 2014. The recipients of the Disease Team Therapy Development III awards were Dr. Dennis Slamon and Dr. Zev Wainberg, whose phase I clinical trial will test a new drug that targets cancer stem cells and has been approved to begin enrolling patients in the US and Canada, and Dr. Donald Kohn, whose first-in-human trial is on stem cell gene therapy for sickle cell disease (SCD).

The announcement of the new awards came on December 12, 2013 at the meeting of the CIRM Independent Citizens Oversight Committee (ICOC) at the Luxe Hotel in Los Angeles. Dr. Owen Witte, Director of the UCLA Broad Stem Cell Research Center, highlighted that the The CIRM support demonstrates that our multidisciplinary Center is at the forefront of translating basic scientific research to new drug and cellular therapies that will revolutionize medicine.

Targeting solid tumor stem cells The Disease Team III grant to Dr. Dennis Slamon and Dr. Zev Wainberg and their US-Canadian collaborative team will support the first in human clinical trial scheduled to open in early 2014. The project builds on Dr. Slamons previous work partially funded by CIRM to develop a drug that targets tumor initiating cells with UCLAs Dr. Zev Wainberg, assistant professor of hematology/oncology and Dr. Tak Mak, director, Campbell Family Institute of the University Health Network in Toronto, Canada. Dr. Slamon, renowned for his research that led to the development of Herceptin, the first FDA-approved targeted therapy for breast cancer, is the director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center, and professor, chief and executive vice chair for research in the division of hematology/oncology.

With investigational new drug approval from the Food and Drug Administration (FDA) and Health Canada, the Canadian governments therapeutic regulatory agency, this trial is an international effort to bring leading-edge stem cell science to patients.

We are delighted to receive this CIRM grant that will drive our translational research from the laboratory to the clinic, Slamon said, and allow us to test our targeted drug in a phase I clinical trial.

The trial is based on the evidence built over the last decade for what has become known as the cancer stem cell hypothesis. According to this hypothesis, cancer stem cells are the main drivers of tumor growth and are also resistant to standard cancer treatments. One view is that cancer stem cells inhabit a niche that prevents cancer drugs from reaching them. Another view is that tumors can become resistant to therapy by a process called cell fate decision, by which some tumor cells are killed by therapy and others become cancer stem cells. These cancer stem cells are believed to be capable of self-renewal and repopulation of tumor cells, resulting in the recurrence of cancer.

The target of the new drug is an enzyme in cancer stem cells and tumor cells called Polo-like kinase 4, which was selected because blocking it negatively affects cell fate decisions associated with cancer stem cell renewal and tumor cell growth, thus stopping tumor growth.

This potential anti-cancer drug is now ready to be tested in humans for the first time. Our goal is to test this novel agent in patients in order to establish safety and then to proceed quickly to rapid clinical development. We are excited to continue this academic collaboration with our Canadian colleagues to test this drug in humans for the first time, said Wainberg. Drs. Slamon, Wainberg, Mak and colleagues will also look for biological indications, called biomarkers, that researchers can use to tell if and how the drug is working.

Link:
UCLA Scientists Taking Stem Cell Research to Patients

Californias government-run stem-cell research agency, on course to spend $3 billion in taxpayer money to find treatments for some of the worlds most intractable diseases, is pushing to accelerate human testing before its financing runs out.

For the California Institute for Regenerative Medicine, time is growing short to fund research that demonstrates the potential of stem cells to help treat everything from cancer to heart disease to spinal cord injuries.

The agency, created by voters in 2004, has given out more than half of its $3 billion from state bonds and must spend the rest by 2017. The largest U.S. funding source for stem-cell research outside the federal government, its under pressure to show results to attract new money from pharmaceutical companies, venture capitalists or even more municipal bonds.

We need to figure out how to keep them going, said Jonathan Thomas, a founding partner of Saybrook Capital LLC in Los Angeles, and chairman of the institutes board, which meets today. We could do public-private partnerships, venture philanthropy, a ballot box.

Embryonic stem cells have the potential to change into any type of cell in the body. They are among the first cells created in embryos after conception. Scientists hope they may replace damaged or missing tissue in the brain, heart and immune system.

California voters approved the bonds after President George W. Bush banned the use of federal funds for research on embryonic stem cells. Since then, other types of stem cells have been shown to act like embryonic cells, relieving some of the debate over the ethics of destroying human embryos to use the cells.

The agencys funding decisions have included a grant of $20 million to a team led by Irv Weissman at the Stanford University School of Medicine, seeking a cure for cancer.

Weissmans team is working on an antibody manufactured with stem cells that allows a cancer patients own immune system to destroy a tumor, instead of relying on toxic radiation or chemotherapy. The antibody counteracts a protein called CD47, which creates what scientists call a dont eat me shield around the cancer. Once that cloak is removed, the patients immune system recognizes the cancer and attacks the tumor, shrinking or eliminating it.

Tests on humans are to begin early next year. The antibody has already worked in mice against breast, colon, ovarian, prostate, brain, bladder and liver cancer.

Two other research projects funded by the California agency are in human trials now -- one targeting HIV, the virus that causes AIDS, and another that regrows cardiac tissue in heart-attack victims.

Visit link:
California’s Stem-Cell Quest Races Time as Money Dwindles

Contact Information

Available for logged-in reporters only

Newswise Stem cell researchers from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have published the first study to identify the origin cells and track the early development of human articular cartilage, providing what could be a new cell source and biological roadmap for therapies to repair cartilage defects and osteoarthritis. These revolutionary therapies could reach clinical trials within three years.

Led by Dr. Denis Evseenko, assistant professor of orthopedic surgery and head of UCLAs Laboratory of Connective Tissue Regeneration, the study was published online ahead of print in Stem Cell Reports on December 12, 2013.

Articular cartilage is a highly specialized tissue formed from cells called chondrocytes that protect the bones of joints from forces associated with load bearing and impact, and allows nearly frictionless motion between the articular surfaces. Cartilage injury and lack of cartilage regeneration often lead to osteoarthritis involving degradation of joints, including cartilage and bone. Osteoarthritis currently affects more than 20 million people in the United States alone, making joint surface restoration a major priority in modern medicine.

Different cell types have been studied with respect to their ability to generate articular cartilage. However, none of the current cell-based repair strategies including expanded articular chondrocytes or mesenchymal stromal cells from adult bone marrow, adipose tissue, sinovium or amniotic fluid have generated long-lasting articular cartilage tissue in the laboratory.

By bridging developmental biology and tissue engineering, Evseenkos discoveries represent a critical missing link providing scientists with checkpoints to tell if the cartilage cells (called chondrocytes) are developing correctly.

We began with three questions about cartilage development, Evseenko said, we wanted to know the key molecular mechanisms, the key cell populations, and the developmental stages in humans. We carefully studied how the chondrocytes developed, watching not only their genes, but other biological markers that will allow us to apply the system for the improvement of current stem cell-based therapeutic approaches.

This research was also the first attempt to generate all the key landmarks that allow generation of clinically relevant cell types for cartilage regeneration with the highest animal-free standards. This means that the process did not rely on any animal components, thus therapeutic products such as stem-cell serums can be produced that are safe for humans.

Evseenko added that in a living organism more than one cell type is responsible for the complete regeneration of tissue, so in addition to the studies involving generation of articular cartilage from human stem cells, he and his team are now trying different protocols using different combinations of adult progenitor cells present in the joint to regenerate cartilage until the best one is found for therapeutic use.

See the rest here:
UCLA Scientists First to Track Joint Cartilage Development in Humans

A groundbreaking attempt to heal eight Parkinson's patients with their own cells could move from research to the clinic next year.

For eight Parkinson's patients seeking treatment with a new form of stem cell therapy, 2014 promises to be a milestone. If all goes well, next year the FDA will give approval to begin clinical trials. And if the patients can raise enough money, the scientists and doctors working with them will have the money to proceed.

Jeanne Loring, a stem cell scientist at The Scripps Research Institute, discusses the status of a project to treat Parkinson's patients with their own cells, turned into the kind of brain cells destroyed in Parkinson's. The project is a collaboration with Scripps Health and the Parkinson's Association of San Diego.

Scientists at The Scripps Research Institute led by Jeanne Loring have taken skin cells from all patients and grown them into artificial embryonic stem cells, called induced pluripotent stem cells. They then converted the cells into dopamine-making neurons, the kind destroyed in Parkinson's disease.

Loring discussed the project's progress on Friday morning at the 2013 World Stem Cell Summit in San Diego.

If animal studies now under way and other requirements are met, doctors at Scripps Health will perform a clinical trial. They will grow neurons until they are just short of maturity, then transplant them into the brains of the respective patients. The cells are expected to complete maturation in the brain, forming appropriate connections with their new neighbors, and begin making dopamine.

Earlier attempts to treat Parkinson's with a stem cell-like therapy mostly failed because of difficulties in quality control of the source, neural cells from aborted fetuses, Loring said. But some patients gained lasting improvement, a tantalizing hint that the trials were on the right track.

In January, a "pre-pre-IND meeting" is planned with the FDA, Loring said.

Also speaking were Ed Fitzpatrick, one of the eight patients, and Kyoto University researcher Jun Takahashi, who is independently trying the same approach in Japan.

Ed Fitzpatrick, one of eight Parkinson's patients in a program to be treated with his own cells, grown into the kind of brain cells destroyed in Parkinson's.

Link:
Stem cells for Parkinson's getting ready for clinic

Cell therapy Definition Cell therapy is the transplantation of human or animal cells to replace or repair damaged tissue. Purpose The purpose of cell therapy is to introduce cells into the body that will grow and replace damaged tissue. Cell therapy differs from conventional stem cell therapy in that the cells injected into the body in cell therapy are already differentiated (e.g., muscle cells, gland cells), whereas conventional stem cell therapy utilizes undifferentiated, usually embryonic cells. Cell therapy has long been used by alternative medicine practitioners who have claimed great benefits; these have not been replicated by conventional medical practitioners. Description The theory behind cell therapy has been in existence for several hundred years. The first recorded discussion of the concept of cell therapy can be traced to Phillippus Aureolus Paracelsus (1493-1541), a German-Swiss physician and alchemist who wrote in his Der grossen Wundartzney (Great Surgery Book) in 1536 that the heart heals the heart, lung heals the lung, spleen heals the spleen; like cures like. Paracelsus and many of his contemporaries agreed that the best way to treat an illness was to use living tissue to restore the ailing. In 1667, at a laboratory in the palace of Louis XIV, Jean-Baptiste Denis (1640-1704) attempted to transfuse blood from a calf into a mentally ill patient. Since blood transfusion is, in effect, a form of cell therapy, this could be the first documented case of this procedure. However, the first recorded attempt at non-blood cellular therapy occurred in 1912 when German physicians attempted to treat children with hypothyroidism (underactive thyroid gland), with thyroid cells. In 1931, Dr. Paul Niehans (1882-1971), a Swiss physician, became known as the father of cell therapy quite by chance. After a surgical accident by a colleague, Niehans attempted to replace a patients severely damaged parathyroid glands with those of a steer. When the patient began to rapidly deteriorate before the transplant could take place, Niehans decided to dice the steers parathyroid gland into fine pieces, mix the pieces in a saline solution, and inject them into the dying patient. He reported that immediately the patient began to improve and, in fact, lived for another 30 years. Cell therapy as alternative medicine Cell therapy as performed by alternative medicine practitioners is very different from the controlled research done by conventional stem cell medical researchers. Alternative practitioners refer to their form of cell therapy by several other different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. The procedure involves the injection of either whole fetal xenogenic (animal) cells (e.g., from sheep, cows, pigs, and sharks) or cell extracts from human tissue. Several different types of cells may be administered simultaneously. Just as Paracelsuss theory of like cures like, the types of cells that are administered correspond in some way with the organ or tissue in the patient that is failing. In other words, the cells are not species specific, but only organ specific. Alternative practitioners cannot explain how this type of cell therapy works, but proponents claim that the injected cells travel to the similar organ from which they were taken to revitalize and stimulate that organs function and regenerate its cellular structure. Supporters of cellular treatment believe that embryonic and fetal animal tissue contain active therapeutic agents distinct from vitamins, minerals, hormones, or enzymes. This theory and these claims are rejected by practitioners of conventional medicine. Proponents of cell therapy claim that it has been used successfully to rebuild damaged cartilage in joints, repair spinal cord injuries, strengthen a weakened immune system, treat autoimmune diseases such as AIDS, and help patients with neurological disorders such as Alzheimers disease, Parkinsons disease, and epilepsy. Further claims of positive results have been made in the treatment of a wide range of chronic conditions such as arteriosclerosis, congenital defects, and sexual dysfunction. The therapy has also been used to treat cancer patients at a number of clinics in Tijuana, Mexico. Most of these claims are anecdotal. None of these application is supported by well-designed, controlled clinical studies. Key Terms Cell therapy as conventional medicine Cell therapy in conventional medicine is still in the research and early clinical trial stage. This research is an outgrowth of stem cell research, and is performed in government-regulated laboratories by traditionally trained scientists. Embryonic stem cells are cells taken from an embryo before they have differentiated (specialized) into such specific cell types as muscle cells, nerve cells, or skin cells. In laboratory test tube and animal experiments, stem cells often can be manipulated into differentiating into specific types cells that have the potential to replace differentiated cells in damaged organs. For example, in early 2008, researchers at the Diabetic Research Institute at the University of Miami in Florida were able to convert embryonic stem cells into insulin-producing cells and use them to treat insulin-dependent diabetes in mice. Stem cells also have been found in bone marrow, and work is underway to see if other cells can be manipulated into transforming into differentiated cells. In January 2009, researchers at Northwestern Universitys Feinberg School of Medicine in Chicago announced that they had used a patients own bone marrow stem cells to improve early symptoms of multiple sclerosis. Researchers noted improvement only in patients with early symptoms; in earlier research those with advanced symptoms had not improved. Other researchers are working on treating symptoms of muscular dystrophy with fully differentiated myoblasts (a kind of muscle cell) with mixed results. Still other are working with using cartilage cells (chondrocyte cells) to repair cartilage in joints such as the knee. Stem cell therapy has potential to treat a wide range of diseases and disorders, but it is, for the most part, still in the test tube and animal research stage of development. Because of the ethical questions raised when the harvesting of stem cells destroys embryos, the United States has placed restrictions on some human stem cell research. These restrictions, however, do not apply to research that does not destroy embryos. However, much stem cell research is being carried out in other countries, especially Thailand, South Korea, and China, where fewer restrictions are placed on obtaining human stem cells for experimentation. A list of FDA-approved clinical trials involving stem cell therapy can be found at http://www.clinicaltrials.gov. Preparations Alternative practitioners use several processes to prepare cells for use. One procedure involves extracting cells from the patient and then culturing them in a laboratory until they multiply to the level needed for transplantation back into the same patient. Another procedure uses freshly removed fetal animal tissue that has been processed and suspended in a saline (salt water) solution. The preparation of fresh cells then may be either injected immediately into the patient or preserved by being freeze-dried or deep-frozen in liquid nitrogen before being injected. Injected cells may or may not be tested for pathogens, such as bacteria, viruses, or parasites, before use. Conventional cell therapy researchers work in laboratories where the growing environment of the cells is highly controlled and monitored to prevent contamination. Precautions Many forms of cell therapy in the United States are highly experimental procedures. Patients should approach any cell therapy treatments with extreme caution, inquire about their proven efficacy and legal use in the United States or their home country, and should only accept treatment only from a licensed physician who should educate the patient completely on the risks and possible side effects involved with cell therapy. These same cautions apply for patients interested in participating in FDA-approved clinical trials of cell therapy treatments. Side effects Because cell therapy encompasses a wide range of treatments and applications and many of these treatments are unproven and highly experimental, the full range of possible side effects of the treatments is not yet known. Anaphylactic shock, immune system reactions, and encephalitis are just a few of the known reported side effects in some patients to date. Patients undergoing cell therapy treatments which use cells transplanted from animals or other humans run the risk of cell rejection, in which the body recognizes the cells as a foreign substance and uses immune system cells to attack and destroy them. Some forms of cell therapy use special coatings on the cells in an attempt to trick the immune system into recognizing the new cells as native to the body. There is also the chance of the cell solution transmitting a bacterial, viral, fungal, or parasitic infection to the patient. Careful screening and testing of cells for pathogens can reduce this risk. Research and general acceptance Cell therapy as alternative healers practice it is generally rejected as effective by the traditionally-trained scientific community. Most of the claims made for these therapies are based on anecdotal evidence and are not backed by controlled clinical trials. While some mainstream cell therapy procedures have shown some success in clinical studies, others are still largely unproven, including cell therapy for cancer treatment. Until large, controlled human clinical studies are performed on cell therapy procedures, they will remain fringe treatments. For Your Information Resources Books Steenblock, David and Anthony G. Payne.Umbilical Cord Stem Cell Therapy: The Gift of Healing from Healthy Newborns. Laguna Beach, CA: Basic Health Publications, 2006. Periodicals Pollack, Andrew. Stem Cell Therapy Controls Diabetes in Mice. New York Times. February 21, 2007 [cited February 2, 2009] http://www.nytimes.com/2008/02/21/health/research/21stem.html. Websites Cellular Therapy. Quackwatch. 2003 [cited February 2, 2009]. http://www.quackwatch.com/01QuackeryRelatedTopics/Cancer/cellular.html. Multiple Sclerosis Reversed with Stem Cell Therapy. New Scientist Health. January 30, 2009 [cited February 2, 2009]. http://www.newscientist.com/article/dn16509-multiple-sclerosis-reversed-with-stem-cell-therapy.html. Organizations Alternative Medicine Foundation. P. O. Box 60016, Potomac, MD 20859. (301) 340-1960. http://www.amfoundation.org. Center for Cell and Gene Therapy. Baylor College of Medicine. One Baylor Place N1002, Houston, TX 77030 (713) 798-1246. http://www.bcm.edu/genetherapy. Cell therapy

Cell Therapy

Alternative-Fringe medicine (1) Live cell therapy (2) The injection of cellular material from organs, foetuses, or embryos of animals to stimulate healing, counteract the effects of ageing, and treat a variety of degenerative diseases such as arthritis, Parkinsons disease, atherosclerosis, and cancer; methods include the use of live cells, freeze-dried cells, cells from specific organs, and whole embryo preparations Molecular medicine (1) Gene therapy, see there (2) Stem cell therapy Quackery Sicca cell treatment

cell

1. the basic structural unit of living organisms.

2. a small more or less enclosed space.

All living cells arise from other cells, either by division of one cell to make two, as in mitosis and meiosis, or by fusion of two cells to make one, as in the union of the sperm and ovum to make the zygote in sexual reproduction.

All cells are bounded by a structure called the cell membrane or plasma membrane, which is a lipid bilayer composed of two layers of phospholipids. Each layer is one molecule thick with the charged, hydrophilic end of the lipid molecules on the surface of the membrane and the uncharged hydrophobic fatty acid tails in the interior of the membrane.

Cells are divided into two classes, eukaryotic cells and prokaryotic cells:

Prokaryotic cells, the bacteria, have no nucleus, and their genetic material, consisting of a single circular naked DNA molecule, is not separated from the rest of the cell by a nuclear membrane.

Original post:
Stem Cells Therapy

Cell therapy hope for rare diseases
Cell therapy hope for rare diseases UK cell therapy trial for rare diseases A trial has begun of a new cell therapy has begun in the UK, and the BBCs Fergus ...

By: World Wide News

Go here to see the original:
Cell therapy hope for rare diseases - Video

Multiple Myeloma Stem Cell Therapy Technique - Gujarati

By: Drmeena Shah

Here is the original post:
Multiple Myeloma Stem Cell Therapy Technique - Gujarati - Video

Multiple Myeloma Stem Cell Therapy Financial Considerations - Gujarati

By: Drmeena Shah

See original here:
Multiple Myeloma Stem Cell Therapy Financial Considerations - Gujarati - Video

stem cell therapy makes senile spot disappear.
"ReLife" was founded by Professor Zhang, a well respected doctor with decades of experience in the medical field. Over the decades, "ReLife" pioneering, country leading experts have been dedicated...

By: IMC ReLife

Read more:
stem cell therapy makes senile spot disappear. - Video

Leukemia is a cancer of white blood cells, or leukocytes. Like other blood cells, leukocytes develop from somatic stem cells. Mature leukocytes are released into the bloodstream, where they work to fight off infections in our bodies.

Leukemia results when leukocytes begin to grow and function abnormally, becoming cancerous. These abnormal cells cannot fight off infection, and they interfere with the functions of other organs.

Successful treatment for leukemia depends on getting rid of all the abnormal leukocytes in the patient, allowing healthy ones to grow in their place. One way to do this is through chemotherapy, which uses potent drugs to target and kill the abnormal cells. When chemotherapy alone can't eliminate them all, physicians sometimes turn to bone marrow transplants.

In a bone marrow transplant, the patient's bone marrow stem cells are replaced with those from a healthy, matching donor. To do this, all of the patient's existing bone marrow and abnormal leukocytes are first killed using a combination of chemotherapy and radiation. Next, a sample of donor bone marrow containing healthy stem cells is introduced into the patient's bloodstream.

If the transplant is successful, the stem cells will migrate into the patient's bone marrow and begin producing new, healthy leukocytes to replace the abnormal cells.

New evidence suggests that bone marrow stem cells may be able to differentiate into cell types that make up tissues outside of the blood, such as liver and muscle. Scientists are exploring new uses for these stem cells that go beyond diseases of the blood.

See original here:
Stem Cells In Use - Learn Genetics

Aegean Process (Stem Cell Therapy with PRP)

By: sapardue

Read the original post:
Aegean Process (Stem Cell Therapy with PRP) - Video

"VAMPIRE FACELIFT STEM CELL and PRP THERAPY" http://www.CLINICell.com

By: ClinicellTech

Original post:
"VAMPIRE FACELIFT STEM CELL and PRP THERAPY" http://www.CLINICell.com - Video

Multiple Myeloma Stem Cell Therapy mp4

By: Drmeena Shah

The rest is here:
Multiple Myeloma Stem Cell Therapy mp4 - Video

Stem Cell Therapy Injections
Stem Cell therapy, is one form of Comprehensive Prolotherapy available for arthritis treatment, and other chronic pain conditions at Caring Medical and Rehab...

By: Rob C

View post:
Stem Cell Therapy Injections - Video